Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end a performance-based funding arrangement originally announced on July 29, 2026. The move, announced by the Canadian oncology company, will result in the return and cancellation of 5,380,683 common shares and the waiver of 2.25 million additional common share purchase warrants, without any additional cash payment by the company.
Under the agreement, Sorbie will return an aggregate of 5,380,683 common shares for cancellation, comprising 2,761,635 shares held by Sorbie Bornholm and 2,619,048 shares held by Sorbie Investments. Sorbie Bornholm will receive the remaining credit support corresponding to C$4,444,444, while Onco-Innovations will relinquish its rights to further payments under the arrangement. The transaction will not require an additional cash payment by the company, according to the press release disseminated on behalf of Onco-Innovations Limited.
The cancellation of 5.38 million shares and the elimination of 2.25 million warrants represent a significant reduction in potential dilution for existing shareholders. By terminating the arrangement, Onco-Innovations also removes the obligation to issue those warrants, which could have weighed on the company's share count in the future. Sorbie Investments will waive its right to receive the additional common share purchase warrants, further simplifying the company's capital structure. The termination remains subject to customary closing conditions, including approval from Cboe Canada, and will take effect on a closing date agreed upon by the parties.
For investors, the termination of the Sorbie funding arrangement may be viewed as a streamlining of Onco-Innovations' financial commitments. The company retains its focus on cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions, and it holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
The full press release can be viewed at https://ibn.fm/nx0ZV. The announcement was distributed through InvestorWire, a wire service that offers UNLIMITED Words on all domestic releases and complimentary Press Release Enhancement. InvestorWire is part of the InvestorBrandNetwork, which leverages the audiences of its 50+ brands to provide follow-up coverage of every release. For more information, visit https://www.investorwire.com. Full terms of use and disclaimers are available at http://ibn.fm/Disclaimer.
